Published in Lancet on July 05, 1980
Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes. CMAJ (1993) 1.86
Survival in treated hypertension: follow up study after two decades. BMJ (1998) 1.64
Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J (Clin Res Ed) (1982) 1.20
Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. Br J Clin Pharmacol (1982) 1.08
Which beta blocker? Br Med J (Clin Res Ed) (1983) 1.00
Effect of long-term treatment with beta-blocking drugs on plasma lipids and lipoproteins. Br Med J (Clin Res Ed) (1981) 0.94
Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. Br J Clin Pharmacol (1986) 0.92
Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy. Cardiovasc Drugs Ther (1989) 0.83
Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmacol (1986) 0.83
Antihypertensive drugs and blood lipids: the Oslo study. Br J Clin Pharmacol (1982) 0.82
The effects of treatment on target organ damage in hypertensive disease. Postgrad Med J (1985) 0.81
Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol. Br J Clin Pharmacol (1983) 0.81
Oslo Hypertension Study. Drugs (1986) 0.80
Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea. Open Cardiovasc Med J (2011) 0.79
Serum lipids and glucose concentrations in subjects using antihypertensive drugs: Finnmark 1977. J Epidemiol Community Health (1983) 0.78
Changes in blood chemistry in hypertensive patients during propranolol therapy. Br J Clin Pharmacol (1984) 0.78
Effects of short term beta adrenoreceptor blockade on serum lipids and lipoproteins in patients with hypertension or coronary artery disease. Br Heart J (1984) 0.76
HDL cholesterol and beta-adrenoceptor blocking agents in a 5 year multifactorial primary prevention trial. Br J Clin Pharmacol (1982) 0.76
Alpha- and beta-blockade in angina pectoris. Drugs (1984) 0.75
Plasma apolipoproteins and lipids in normal persons and patients with hypertension. Korean J Intern Med (1986) 0.75
Beta adrenoceptor blockade and responses of serum lipids to a meal and to exercise. Br Med J (Clin Res Ed) (1984) 0.75
The pharmacological basis for the use of alpha 1-adrenoceptor antagonists in the treatment of essential hypertension. Br J Clin Pharmacol (1986) 0.75
Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis. Br J Clin Pharmacol (2016) 0.75
The effects of diuretics and adrenergic-blocking agents on plasma lipids. West J Med (1986) 0.75
Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients. Br J Clin Pharmacol (1984) 0.75
Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet (1981) 7.05
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet (2001) 6.31
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med (1980) 3.19
Benefit of a stroke unit: a randomized controlled trial. Stroke (1991) 3.13
The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med (1990) 2.85
Coronary risk factors and socioeconomic status. The Oslo study. Lancet (1976) 2.67
Risk factors for sports injuries--a methodological approach. Br J Sports Med (2003) 2.59
Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation (1996) 2.55
Four-year mortality by some socioeconomic indicators: the Oslo study. J Epidemiol Community Health (1980) 2.48
The cardiovascular disease study in Norwegian counties. Background and organization. Acta Med Scand Suppl (1979) 2.46
Lung cancer and air pollution: a 27 year follow up of 16 209 Norwegian men. Thorax (2003) 2.43
A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol (2004) 2.37
The Oslo study. Cardiovascular disease in middle-aged and young Oslo men. Acta Med Scand Suppl (1975) 2.30
Mortality in relation to smoking history: 13 years' follow-up of 68,000 Norwegian men and women 35-49 years. J Clin Epidemiol (1993) 2.28
Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens (1994) 2.19
Reliability of questionnaire information on cardiovascular disease and diabetes: cardiovascular disease study in Finnmark county. J Epidemiol Community Health (1982) 2.11
The Oslo diet-heart study. Eleven-year report. Circulation (1970) 2.10
Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J (1997) 2.07
Sex differences in risk factors for clinical diabetes mellitus in a general population: a 12-year follow-up of the Finnmark Study. Am J Epidemiol (1998) 2.06
Prevention of hamstring strains in elite soccer: an intervention study. Scand J Med Sci Sports (2007) 2.03
The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine (Phila Pa 1976) (1993) 2.01
Preventing injuries in female youth football--a cluster-randomized controlled trial. Scand J Med Sci Sports (2008) 1.90
The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. Acta Med Scand Suppl (1966) 1.80
Differences between echocardiographic measurements of left ventricular dimensions and function by local investigators and a core laboratory in a 2-year follow-up study of patients with an acute myocardial infarction. Eur J Echocardiogr (2002) 1.69
Five-year mortality in the city of Bergen, Norway, according to age, sex and blood pressure. Acta Med Scand (1976) 1.60
[Cardiovascular screenings in Norwegian counties. Background and implementation. Status of risk pattern during the period 1986-90 among persons aged 40-42 years in 14 counties]. Tidsskr Nor Laegeforen (1991) 1.55
High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study. Br Med J (1978) 1.50
Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma. Arteriosclerosis (1990) 1.46
Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol (2006) 1.46
Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The Oslo study. Am J Med (1978) 1.42
Childhood traumas and psychosocial characteristics of 50-year-old men with essential hypertension. J Psychosom Res (1990) 1.42
[Doxazosin (Carduran)--a research survey]. Tidsskr Nor Laegeforen (1993) 1.39
[Is blood pressure treatment as effective in a population setting as in controlled studies?]. Tidsskr Nor Laegeforen (1994) 1.39
[Alpha blockaders--first or second line antihypertensive agents?]. Tidsskr Nor Laegeforen (1993) 1.38
Dystonia and dyskinesia in glutaric aciduria type I: clinical heterogeneity and therapeutic considerations. Mov Disord (1994) 1.36
Oslo Study Diet and Antismoking Trial. Results after 102 months. Am J Med (1986) 1.35
Pacemaker therapy in sino-atrial block complicated by paroxysmal tachycardia. Br Heart J (1970) 1.32
Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo Study. Stroke (1993) 1.31
The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med (2006) 1.29
Ethnicity and sex are strong determinants of diabetes in an urban Western society: implications for prevention. Diabetologia (2005) 1.28
Serum thiocyanate and smoking: interpretation of serum thiocyanate levels observed in a large health study. Scand J Clin Lab Invest (1986) 1.28
Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care (1997) 1.27
Association of cardiac autonomic function and the development of hypertension: the ARIC study. Am J Hypertens (1996) 1.26
High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur Heart J (1992) 1.25
Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein. Biochem Pharmacol (1978) 1.23
Physical activity at work and at leisure in relation to coronary risk factors and social class. A 4-year mortality follow-up. The Oslo study. Acta Med Scand (1981) 1.22
Combined diet and exercise intervention reverses the metabolic syndrome in middle-aged males: results from the Oslo Diet and Exercise Study. Scand J Med Sci Sports (2007) 1.19
Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. J Intern Med (1998) 1.18
Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis (2010) 1.17
Coronary risk factors in various occupational groups: the Oslo study. Br J Prev Soc Med (1977) 1.16
Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men. Am J Epidemiol (1989) 1.16
Body height, cardiovascular risk factors, and risk of stroke in middle-aged men and women. A 14-year follow-up of the Finnmark Study. Circulation (1996) 1.15
Identity of the cholesterol-raising factor from boiled coffee and its effects on liver function enzymes. J Lipid Res (1994) 1.15
Possible metabolic side effects of beta-adrenergic blocking drugs. Br Med J (1978) 1.14